WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 21, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Daniel Char , JD, has been appointed Senior Vice President and Chief Legal Officer.
ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin ® Use VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the Companion Diagnostic to Identify Ovarian Cancer Patients
Launch Preparations Completed Ahead of November 28, 2022 PDUFA Date Presentations at ESMO, IGCS, and ESGO Highlight Mirvetuximab’s Potential to Become New Standard of Care and Combination Agent of Choice in FRα-Positive Ovarian Cancer Initial Data from Pivotal Phase 2 CADENZA Study Demonstrated
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 31, 2022 , the compensation committee of the Company’s Board of Directors approved
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith , Senior Vice President and Chief Commercial Officer (CCO), will be
Patients with Extended Treatment Benefit Showed an Objective Response Rate of 77.5% and a Median Duration of Response of 22.1 Months Overall Adverse Event Profile Observed Consistent with Known Safety Profile of Mirvetuximab with Minimal Cumulative Toxicities Study Outcomes in Patients with
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 3, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2022 , the compensation committee of the Company’s Board of Directors approved
Mirvetuximab Plus Bevacizumab Demonstrated Meaningful Efficacy in Recurrent FRα-Positive Ovarian Cancer Across a Broad Range of FRα Expression Regardless of Prior Treatment; Data to be Highlighted in Oral Presentation Additional Clinical Benefit Outcomes from Pivotal SORAYA Study Also Reported
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 14, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, will participate in a fireside chat at the upcoming